CDEK
← All drugs Report issue

vabicaserin

Small moleculeexperimental

Vabicaserin was a novel antipsychotic and anorectic under development by Wyeth. As of 2010 it is no longer in clinical trials for the treatment of psychosis. It was also under investigation as an antidepressant but this indication appears to have been dropped as well. — Wikipedia

Clinical trial activity

9 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2006 (NCT00265551)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

c1cc2c3c(c1)[C@H]1CCC[C@H]1CN3CCNC2
Mol. weight
228.34 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • sca-136
  • sca-136
  • sca-136
  • vabicaserin
  • vabicaserin
  • vabicaserin
  • vabicaserin
  • vabicaserin hcl
  • vabicaserin hcl
  • vabicaserin hydrochloride
  • vabicaserin hydrochloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00928551Phase 1Jun 1, 2009Pfizer, Wyeth
NCT00768612Phase 2Nov 1, 2008Pfizer, Wyeth
NCT00563706Phase 2Dec 1, 2007Pfizer
NCT00541996Phase 1Aug 1, 2007Pfizer, Wyeth
NCT00505973Phase 1Jul 1, 2007Pfizer, Wyeth
NCT00458107Phase 1Apr 1, 2007Pfizer, Wyeth
NCT00420706Phase 1Dec 1, 2006Pfizer, Wyeth
NCT00447941Phase 1Jun 1, 2006Pfizer, Wyeth
NCT00265551Phase 2Jan 1, 2006Pfizer, Wyeth
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit9922006
WyethFor profit8022006
2 organizations
Page 1 / 1